{"id":"dexamethasone-rituximab-cyclophosphamide-bortezomib","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Neuropathy (bortezomib-related)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Immunosuppression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexamethasone is a corticosteroid that suppresses immune function and promotes apoptosis. Rituximab is a monoclonal antibody targeting CD20 on B cells. Cyclophosphamide is an alkylating agent causing DNA damage. Bortezomib is a proteasome inhibitor that triggers apoptosis in plasma cells by preventing protein degradation. Together, these agents target multiple pathways in hematologic malignancies, particularly multiple myeloma and B-cell lymphomas.","oneSentence":"This combination regimen uses a corticosteroid, B-cell depleting antibody, alkylating agent, and proteasome inhibitor to suppress immune cells and induce apoptosis in malignant plasma cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:15.134Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"B-cell non-Hodgkin lymphoma"},{"name":"Waldenström macroglobulinemia"}]},"trialDetails":[{"nctId":"NCT05736419","phase":"PHASE2","title":"A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-02-09","conditions":"Sickle Cell Disease, Thalassemia, Beta, Thalassemia","enrollment":24},{"nctId":"NCT03136146","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-09","conditions":"Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia","enrollment":42},{"nctId":"NCT02844322","phase":"PHASE4","title":"The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-05","conditions":"Waldenström Macroglobulinemia","enrollment":35},{"nctId":"NCT04776850","phase":"EARLY_PHASE1","title":"Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-29","conditions":"Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia","enrollment":""},{"nctId":"NCT01788020","phase":"PHASE3","title":"Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2013-11","conditions":"Waldenström's Macroglobulinemia","enrollment":202},{"nctId":"NCT05293509","phase":"PHASE2","title":"Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-02","conditions":"Stem Cell Transplantation","enrollment":""},{"nctId":"NCT00477412","phase":"PHASE1, PHASE2","title":"Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-04-03","conditions":"Mantle Cell Lymphoma","enrollment":107},{"nctId":"NCT00598169","phase":"PHASE1","title":"Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2007-11","conditions":"Lymphoma","enrollment":23},{"nctId":"NCT00581776","phase":"PHASE2","title":"Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2005-05","conditions":"Mantle Cell Lymphoma","enrollment":30},{"nctId":"NCT00711828","phase":"PHASE2","title":"Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2008-08","conditions":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma","enrollment":21},{"nctId":"NCT00413959","phase":"PHASE2","title":"VELCADE,Rituximab,Cyclophosphamide and Decadron","status":"TERMINATED","sponsor":"Oncology Specialists, S.C.","startDate":"2006-08","conditions":"Lymphoma, Non-Hodgkin, Lymphoma, B-Cell","enrollment":12},{"nctId":"NCT00504751","phase":"PHASE2","title":"Phase II Study of \"VIPER\" Chemotherapy in Rel/Ref DLBCL","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2007-05","conditions":"Non-Hodgkin's Lymphoma","enrollment":15},{"nctId":"NCT02971982","phase":"PHASE1, PHASE2","title":"PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2016-10","conditions":"Treatment","enrollment":40},{"nctId":"NCT00723658","phase":"PHASE2","title":"S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2008-09","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT00433537","phase":"PHASE2","title":"Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-05","conditions":"Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma","enrollment":77}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib","genericName":"Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib","companyName":"University of Ulm","companyId":"university-of-ulm","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination regimen uses a corticosteroid, B-cell depleting antibody, alkylating agent, and proteasome inhibitor to suppress immune cells and induce apoptosis in malignant plasma cells. Used for Multiple myeloma, B-cell non-Hodgkin lymphoma, Waldenström macroglobulinemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}